Home LiteratureArticle Details
PMID: 8926085 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Expression and immunogenicity of pertussis toxin S1 subunit-tetanus toxin fragment C fusions in Salmonella typhi vaccine strain CVD 908.

Infection and immunity ·Vol. 64 ·No. 10 ·1996-10-00 ·Pages 4172-81

Barry EM, Gomez-Duarte O, Chatfield S, Rappuoli R, Pizza M, Losonsky G, Galen J, Levine MM

Abstract

Salmonella typhi vaccine strain CVD 908 can deliver heterologous antigens to the host immune system following mucosal immunization. Stable expression of foreign proteins in Salmonella cells often requires antigen-specific engineering strategies. Fusion of antigens to stabilizing proteins has proven to be a successful strategy for rescuing otherwise unstable proteins. We designed plasmids to allow the fusion of antigens to the amino terminus or carboxyl terminus of fragment C of tetanus toxin, separated by a 4-amino-acid hinge region. Towards the ultimate goal of developing a live oral diphtheria-pertussis-tetanus vaccine, we used these plasmids to stably express the S1 subunit of pertussis toxin in CVD 908. Driven by the anaerobically inducible nirB promoter, the S1 subunit alone was expressed poorly in Salmonella cytoplasm. In contrast, hybrid proteins with S1 fused to either the amino or carboxyl terminus of fragment C were expressed at a high level in CVD 908 and were recognized in Western blot (immunoblot) analysis by monoclonal antibodies directed to S1 and to fragment C. Mice were immunized by the oral or intranasal routes with CVD 908 derivatives harboring these recombinant plasmids. All fusion proteins elicited serum antibody responses to fragment C following intranasal immunization, whereas oral inoculation did not. The configuration of antigens constituting the fusion was critical; S1 fused to the amino terminus of fragment C was less effective than S1 fused to the carboxyl terminus in generating anti-fragment C antibodies. CVD 908 expressing truncated S1 fused to the carboxyl terminus of fragment C elicited neutralizing serum pertussis antitoxin following intranasal immunization of mice.

MeSH Terms
Animals Antibodies, Bacterial/blood CHO Cells Cricetinae Female Immunization Mice Mice, Inbred BALB C Peptide Fragments/immunology Pertussis Toxin Recombinant Fusion Proteins/immunology Salmonella typhi/genetics,immunology Tetanus Toxin/immunology Vaccines, Synthetic/immunology Virulence Factors, Bordetella/immunology
Chemicals
Antibodies, Bacterial Peptide Fragments Recombinant Fusion Proteins Tetanus Toxin Vaccines, Synthetic Virulence Factors, Bordetella tetanus toxin fragment C Pertussis Toxin
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Barry E M
Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA. [email protected]
Gomez-Duarte O
Chatfield S
Rappuoli R
Pizza M
Losonsky G
Galen J
Levine M M
References (43)
43 references, click to expand
  1. The A protomer of islet-activating protein, pertussis toxin, as an active peptide catalyzing ADP-ribosylation of a membrane protein.
    Arch Biochem Biophys. 1983 Jul 1;224(1):290-8 PMID: 6683482
  2. A role of the B-oligomer moiety of islet-activating protein, pertussis toxin, in development of the biological effects on intact cells.
    J Biol Chem. 1983 Jun 10;258(11):6756-61 PMID: 6343381
  3. Monoclonal antibody against pertussis toxin: effect on toxin activity and pertussis infections.
    Infect Immun. 1984 Nov;46(2):422-8 PMID: 6094351
  4. Pertussis toxin gene: nucleotide sequence and genetic organization.
    Science. 1986 Jun 6;232(4755):1258-64 PMID: 3704651
  5. Virulence factors of Bordetella pertussis.
    Annu Rev Microbiol. 1986;40:661-86 PMID: 2877614
  6. Staphylococcus aureus-stimulated human mononuclear leucocyte-conditioned medium augments the basal and stimuli-induced neutrophil respiratory burst and degranulation.
    Immunology. 1987 Mar;60(3):431-8 PMID: 3570357
  7. Live oral Salmonella vaccines: potential use of attenuated strains as carriers of heterologous antigens to the immune system.
    Parasite Immunol. 1987 Mar;9(2):151-60 PMID: 3106921
  8. Location and sequence of the promoter of the gene for the NADH-dependent nitrite reductase of Escherichia coli and its regulation by oxygen, the Fnr protein and nitrite.
    J Mol Biol. 1987 Aug 20;196(4):781-8 PMID: 2445993
  9. Mutational analysis of the nucleotide sequence at the FNR-dependent nirB promoter in Escherichia coli.
    Nucleic Acids Res. 1989 Jan 11;17(1):135-45 PMID: 2536149
  10. Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function.
    Hybridoma. 1989 Feb;8(1):37-51 PMID: 2466764
  11. Selective delivery of antigens by recombinant bacteria.
    Curr Top Microbiol Immunol. 1989;146:35-49 PMID: 2659274
  12. Mutants of pertussis toxin suitable for vaccine development.
    Science. 1989 Oct 27;246(4929):497-500 PMID: 2683073
  13. Cloning and expression of functional fragment C of tetanus toxin.
    Infect Immun. 1990 Apr;58(4):1004-9 PMID: 2318526
  14. Characterization of genetically inactivated pertussis toxin mutants: candidates for a new vaccine against whooping cough.
    Infect Immun. 1990 May;58(5):1308-15 PMID: 2323818
  15. Oral vaccination of mice against tetanus by use of a live attenuated Salmonella carrier.
    Infect Immun. 1990 May;58(5):1323-6 PMID: 2182542
  16. Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin.
    Infect Immun. 1990 Jun;58(6):1518-26 PMID: 2341166
  17. Protective activities in mice of monoclonal antibodies against pertussis toxin.
    Infect Immun. 1990 Oct;58(10):3369-74 PMID: 1698179
  18. High level heterologous expression in E. coli using the anaerobically-activated nirB promoter.
    Nucleic Acids Res. 1991 Jun 11;19(11):2889-92 PMID: 2057350
  19. Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies.
    Infect Immun. 1991 Oct;59(10):3832-5 PMID: 1894382
  20. Antibody responses in the lungs of mice following oral immunization with Salmonella typhimurium aroA and invasive Escherichia coli strains expressing the filamentous hemagglutinin of Bordetella pertussis.
    Infect Immun. 1991 Dec;59(12):4391-7 PMID: 1937797
  21. Construction of genetically defined double aro mutants of Salmonella typhi.
    Vaccine. 1991 Nov;9(11):810-6 PMID: 1759503
  22. Japanese clinical experiences with acellular pertussis vaccines.
    Dev Biol Stand. 1991;73:5-9 PMID: 1778333
  23. Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.
    Vaccine. 1992;10(7):443-6 PMID: 1609547
  24. Transforming growth factor-beta in disease: the dark side of tissue repair.
    J Clin Invest. 1992 Jul;90(1):1-7 PMID: 1634602
  25. Characterization of a Salmonella typhimurium aro vaccine strain expressing the P.69 antigen of Bordetella pertussis.
    Infect Immun. 1992 Oct;60(10):3994-4002 PMID: 1398911
  26. Specific lung mucosal and systemic immune responses after oral immunization of mice with Salmonella typhimurium aroA, Salmonella typhi Ty21a, and invasive Escherichia coli expressing recombinant pertussis toxin S1 subunit.
    Infect Immun. 1992 Oct;60(10):4260-8 PMID: 1398937
  27. Use of the nirB promoter to direct the stable expression of heterologous antigens in Salmonella oral vaccine strains: development of a single-dose oral tetanus vaccine.
    Biotechnology (N Y). 1992 Aug;10(8):888-92 PMID: 1368983
  28. Construction of a diphtheria toxin A fragment-C180 peptide fusion protein which elicits a neutralizing antibody response against diphtheria toxin and pertussis toxin.
    Infect Immun. 1992 Dec;60(12):5071-7 PMID: 1452339
  29. Immunogenicity and efficacy of oral or intranasal Shigella flexneri 2a and Shigella sonnei proteosome-lipopolysaccharide vaccines in animal models.
    Infect Immun. 1993 Jun;61(6):2390-5 PMID: 8500877
  30. Neutralizing antibodies and immunoprotection against pertussis and tetanus obtained by use of a recombinant pertussis toxin-tetanus toxin fusion protein.
    Infect Immun. 1994 Feb;62(2):449-56 PMID: 7507893
  31. Salmonella typhi vaccine strain CVD 908 expressing the circumsporozoite protein of Plasmodium falciparum: strain construction and safety and immunogenicity in humans.
    J Infect Dis. 1994 Apr;169(4):927-31 PMID: 8133113
  32. Construction, expression, and immunogenicity of multiple tandem copies of the Schistosoma mansoni peptide 115-131 of the P28 glutathione S-transferase expressed as C-terminal fusions to tetanus toxin fragment C in a live aro-attenuated vaccine strain of Salmonella.
    J Immunol. 1994 Dec 15;153(12):5634-42 PMID: 7527446
  33. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants.
    Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1644-8 PMID: 7878032
  34. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres.
    Infect Immun. 1995 Apr;63(4):1195-200 PMID: 7890372
  35. A placebo-controlled trial of a pertussis-toxoid vaccine.
    N Engl J Med. 1995 Oct 19;333(16):1045-50 PMID: 7675047
  36. Simultaneous expression of CFA/I and CS3 colonization factor antigens of enterotoxigenic Escherichia coli by delta aroC, delta aroD Salmonella typhi vaccine strain CVD 908.
    Vaccine. 1995 Jul;13(10):939-46 PMID: 7483768
  37. Construction and characterization of a Salmonella typhi-based human immunodeficiency virus type 1 vector vaccine.
    Vaccine. 1995 Apr;13(6):561-9 PMID: 7483777
  38. Expression of fragment C of tetanus toxin fused to a carboxyl-terminal fragment of diphtheria toxin in Salmonella typhi CVD 908 vaccine strain.
    Vaccine. 1995 Nov;13(16):1596-602 PMID: 8578848
  39. Degradation of abnormal proteins in Escherichia coli (protein breakdown-protein structure-mistranslation-amino acid analogs-puromycin).
    Proc Natl Acad Sci U S A. 1972 Feb;69(2):422-6 PMID: 4551144
  40. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines.
    Nature. 1981 May 21;291(5812):238-9 PMID: 7015147
  41. Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model.
    Biochemistry. 1982 Oct 26;21(22):5516-22 PMID: 6293544
  42. Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin.
    Infect Immun. 1983 Jun;40(3):1198-203 PMID: 6682833
  43. The concept of pertussis as a toxin-mediated disease.
    Pediatr Infect Dis. 1984 Sep-Oct;3(5):467-86 PMID: 6093069
Article Info
Journal
Infection and immunity
Abbr.
Infect Immun
ISSN
0019-9567
Published
1996-10-00
Pages
4172-81
Language
English
Region
United States
NLM ID
0246127
PMCID
PMC174353
Subset
IM
Grants
NIAID NIH HHS · N01 AI15096 · United States
NIAID NIH HHS · N01 AI45251 · United States
PHS HHS · R01A29471 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]